Key result
End-stage renal disease was associated with significantly higher muscle sympathetic nerve activity (37.3 vs 23.1 bursts/min, P=0.025) but not skin sympathetic nerve activity compared to controls.
Why the study?
Is sympathetic overactivity in end-stage renal disease generalized to include the skin distribution?
Population
8 patients with end-stage renal disease (ESRD) and 8 controls (n=16)
Design
Case-control
Authors
Loading...
SSNA in ESRD remains unmeasured; leaves open whether sympathetic overactivity generalizes beyond baroreflex control.
Case-Control (n=16)
Is sympathetic overactivity in end-stage renal disease generalized to include the skin distribution?
Absolute Event Rate: 37.3% vs 23.1%
p-value: p=0.025
In patients with end-stage renal disease, sympathetic overactivity is directed to muscle but not skin, a differential distribution similar to that seen in heart failure and obesity.
Park et al. (2008) conducted a case-control in End-stage renal disease (n=16). End-stage renal disease vs. Controls was evaluated on Muscle sympathetic nerve activity (MSNA) (p=0.025). End-stage renal disease was associated with significantly higher muscle sympathetic nerve activity (37.3 vs 23.1 bursts/min, P=0.025) but not skin sympathetic nerve activity compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: